TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06239064

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic testing via blood collection
Description: blood collection
Study: NCT06395649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical rTMS to M1
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the High connectivity target
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the low connectivity target
Description: The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT06395649

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
Study: NCT04856085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT06096623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Survey
Description: Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
Study: NCT05026983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06547151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMOR-1
Description: Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline Calcium Carbonate
Description: Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
Study: NCT05655702

Intervention type: OTHER
Group type: OTHER
Intervention: Community based TB intervention
Description: * 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts.
Study: NCT05338268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Loneliness
Description: CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study: NCT06104605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Institutional interventions
Description: Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCPs interventions
Description: Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local doctors of chiropractic (DCs), information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient interventions
Description: Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
Study: NCT05582850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-9081 - dose escalation
Description: Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-9081 - expansion
Description: A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
Study: NCT05966064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 120 Mg/1.7 Ml Inj
Description: Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo randomized at baseline and after 3 months
Study: NCT06046612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
Description: The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
Study: NCT05755256

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: After randomization, participants will consume the probiotic for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, participants will consume the placebo for 12 weeks.
Study: NCT04906395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOL2506
Description: Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg once daily or 10 mg 2 times daily - either tablet or solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Tablets
Description: One 2.5 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole Tablets
Description: One 1 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane Tablets
Description: One 25 mg tablet taken orally once daily
Study: NCT05575219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine (without protocolized initiation)
Description: Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (protocolized initiation)
Description: * Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of \>/= 168 hours or with infusion time of 120-167 hours at doses \>/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours).
Study: NCT05496036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400mg IV
Study: NCT05868486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing for Cancer Risk
Description: Undergo germline testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy testing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Whole Body without Contrast
Description: Undergo whole body MRI without contrast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT06466135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL0921
Description: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
Study: NCT05341557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-371153
Description: Subjects will receive BPI-371153 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-371153
Description: Subjects will receive BPI-371153 until disease progression
Study: NCT06060665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg
Description: Seladelpar 10 mg one capsule daily for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One capsule daily for up to 52 weeks
Study: NCT06041256

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AURN001
Description: Corneal Endothelial Cells and Y27632

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AURN001
Description: Corneal Endothelial Cells and Y27632
Study: NCT06021782

Intervention type: OTHER
Intervention: All subjects-Observation
Description: The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
Study: NCT06545682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib + Pembrolizumab
Description: Given by mouth (PO) Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib + Pembrolizumab
Description: Given by mouth (PO) Given by vein (IV)
Study: NCT06543810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hula for Parkinson's
Description: A feasibility study for a Hula program for Parkinson's Disease patients.
Study: NCT06184568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
Study: NCT04726280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 10 ml extrafascial interscalene brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 20 ml extrafascial interscalene brachial plexus block
Study: NCT06503016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine
Description: Administration of Phosphocreatine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution of NaCl 0.9%
Study: NCT05943535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study: NCT05834712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile platform or not mobile platform
Description: Intervention using WeChat

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile platform or not mobile platform
Description: Intervention using WeChat
Study: NCT06372860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding
Description: Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
Study: NCT05655325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Description: A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Health education and stretching
Study: NCT04683848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921
Description: Solution for infusion; Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study: NCT05304377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-001
Description: orally once or twice daily
Study: NCT05841394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: 40 mg i.v. twice daily (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole Sodium
Description: 10 mg i.v. once daily, 20 mg i.v. in the first day.
Study: NCT05153239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
Study: NCT05374603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib combine with Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: savolitinib plus durvalumab
Study: NCT06184568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
Study: NCT05917288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care will be administered
Study: NCT04915170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
Study: NCT06229028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand rehabilitation with verbal explanation
Description: Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand rehabilitation with patient information and exercise forms
Description: hand rehabilitation with patient information and exercise forms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand rehabilitation with video recording
Description: hand rehabilitation with video recording
Study: NCT06126224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT06560463

Intervention type: DEVICE
Intervention: Access to Dexcom G7 CGM Data
Description: Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
Study: NCT03843190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take of Pounds Sensibly (TOPS)
Description: Dietician-facilitated classes

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: At end of study, offered peer-led classes to attend.
Study: NCT05161715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 10mg obicetrapib